TCTMD

ALONE-AF: Stopping OAC After Ablation Doesn’t Reduce Cognitive Function

CHICAGO, IL—When patients stop taking oral anticoagulation (OAC) after they’ve been free of atrial fibrillation (AF) ...
Medscape

ISCHEMIA Substudy Data Just Don't Add Up, Cardiac Surgeons Say

A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...
Medscape

Data Concerns Mount Despite ISCHEMIA Substudy Correction

A long-standing request to clarify data irregularities in a 2021 ISCHEMIA substudy resulted in the publication of one correction, with a second correction in the works. Further, the lone cardiac ...
TCTMD

Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System

BASKING RIDGE, N.J. -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters ...
Healio

VIDEO: ‘Interesting’ Lung-MAP substudy data at ASCO

Please provide your email address to receive an email when new articles are posted on . In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ...
EurekAlert!

Minimally invasive percutaneous arterial bypass shows strong outcome regardless of distal vessel flow

New findings from a DETOUR2 substudy show that minimally invasive percutaneous transmural arterial bypass (PTAB) may offer a ...
Business Wire

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing ...
ascopubs.org

Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)–directed phase II study of carboplatin in patients (Pts) with ...

Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab ...